Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROLINGUAL vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute relief of an angina pectoris attack,Prophylaxis of angina pectoris before activities that may provoke an attack (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
2-3 minutes for sublingual nitroglycerin; rapid decline due to extensive first-pass metabolism and high clearance (30-40 L/min). Clinical context: extremely short half-life necessitates continuous or frequent dosing for sustained effect.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Nitroglycerin is extensively metabolized in the liver by glutathione-S-transferases and in vascular smooth muscle by mitochondrial aldehyde dehydrogenase (ALDH2), producing dinitrate metabolites (1,2- and 1,3-glyceryl dinitrate) and mononitrates.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Renal (primarily as glucuronide conjugates and denitrated metabolites): ~60-80%; Fecal: ~20-40%; Biliary: negligible. Less than 1% excreted unchanged.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
~60% bound, primarily to albumin; low affinity, allowing rapid equilibration with tissues.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
~3 L/kg (0.1-0.2 L/kg for parent drug; larger due to extensive tissue distribution including vascular smooth muscle). High Vd reflects extensive uptake into vessel walls and other tissues.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Sublingual: ~40-60% (avoiding first-pass hepatic metabolism); Oral: <1% (extensive presystemic clearance by hepatic glutathione-organic nitrate reductase).
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No dose adjustment required for any GFR level.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh A: no adjustment; Child-Pugh B: consider dose reduction (e.g., 1 spray); Child-Pugh C: avoid use or use extreme caution with reduced dose.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Not established in pediatric patients for sublingual spray; avoid use in children.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Start with lower dose (1 spray) due to increased sensitivity and risk of hypotension.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Do not use NITROLINGUAL with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) or soluble guanylyl cyclase (s GC) stimulators (e.g., riociguat), as severe hypotension, syncope, or myocardial ischemia can occur.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Hypotension: May cause severe hypotension, especially in volume-depleted patients or those with low systolic blood pressure.,Headache: Common and may be severe; tolerance may develop.,Tolerance: Continuous or frequent use may lead to tolerance, requiring nitrate-free intervals.,Abrupt withdrawal: May precipitate angina; taper if discontinuing long-term therapy.,Hypertrophic cardiomyopathy: May worsen outflow obstruction.,Increased intracranial pressure: Use cautiously in patients with elevated intracranial pressure (e.g., cerebral hemorrhage).
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nitroglycerin or any component of the formulation,Concurrent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) or s GC stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis, cardiac tamponade, restrictive cardiomyopathy,Acute myocardial infarction with low filling pressure (e.g., right ventricular infarction)
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
No specific food interactions. Avoid alcohol, which can exacerbate hypotension. Maintain adequate hydration.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin caused decreased fetal weight and increased fetal resorptions at doses 50 times the human dose. Risk cannot be ruled out; use only if clearly needed. No known teratogenicity in first trimester, but caution in third trimester due to maternal hypotension risk.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Nitroglycerin is excreted in human milk in small amounts. M/P ratio unknown. No adverse effects reported in breastfeeding infants. Caution when administered to nursing women.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No specific dose adjustment recommended for pregnancy. Use lowest effective dose due to increased plasma volume and clearance. Monitor for hypotension, which may be more pronounced in pregnancy. Titrate based on clinical response.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
NITROLINGUAL (nitroglycerin sublingual spray) is first-line for acute angina. Administer 1-2 sprays at onset of chest pain; may repeat every 5 minutes up to 3 doses. Avoid in patients with severe hypotension (SBP <90 mm Hg), right ventricular infarction, or concomitant use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) within 24-48 hours. Monitor for orthostatic hypotension; patient should sit or lie down during administration. The spray is absorbed via oral mucosa; do not inhale or swallow. Onset: 1-3 minutes; duration: 30-60 minutes. Do not shake canister; prime before first use or if not used for >6 weeks.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Use 1-2 sprays under or on the tongue at first sign of chest pain.,Do not shake the canister; hold it upright and spray onto or under the tongue.,Avoid swallowing or inhaling the spray; let it absorb through the oral mucosa.,Wait 5 minutes after the first dose; if chest pain persists, repeat up to 3 doses total.,If pain is not relieved after 3 doses, seek emergency medical help immediately.,Do not take with erectile dysfunction medications (e.g., sildenafil, tadalafil) within 24-48 hours.,Sit or lie down when using the spray to prevent dizziness or fainting.,Store at room temperature away from heat; do not freeze. Check expiration date.,Prime the spray before first use (spray 5 times into air) or if not used for 6 weeks (spray once).,Common side effects: headache, dizziness, flushing, low blood pressure.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROLINGUAL vs IMDUR, answered by our medical review team.
NITROLINGUAL is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROLINGUAL and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROLINGUAL is: 1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROLINGUAL and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROLINGUAL is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin caused decreased fetal weight and increased fetal resorptions at doses 50 times th. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.